Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2001

View Archived Issues

Specific small-molecule inhibitor of IgE synthesis identified at Avanir

Aspirin and warfarin equieffective in the prevention of recurrent ischemic stroke

New chemogenomics information system to be born out of MDS Pharma and Iconix alliance

Georgetown University licenses PBR patent to Samaritan

ViroPharma to join Aventis in Allegra and Nasacort promotion

Theratechnologies and Alza collaborate on transdermal delivery of peptide product

Initiation of phase III trials of Antegren in multiple sclerosis and Crohn's disease

Synaptic files IND application for antidepressant drug

Aradigm completes phase IIb trials of AERx Pain Management System

Telik files IND application for TLK-199, a small molecule for myelodysplastic syndrome

Pagoclone shows promising results in treatment of generalized anxiety disorder

Celltech announces product pipeline changes

Azalides active against MLS-resistant strains prepared at Pliva

Non-nucleoside anti-HCMV agent designed by Tularik being tested in patients

Known antihypertensive drug introduced by Santen for glaucoma in Japan

Second-generation glycopeptide dalbavancin the subject of five ICAAC presentations

AstraZeneca's new oxazolidinones active against resistant bacterial strains

Diazabicyclic compounds modulate acetylcholine receptors to induce analgesia

Bayer presents peptidomimetic integrin antagonists

Compounds with the ability to activate nicotinic acetylcholine receptors described by Suntory

Daiichi patents new series of anticoagulants

Potential antidepressant dropped from Yamanouchi pipeline

Novogen cleared to start phase Ib/IIa phenoxodiol trial in leukemia

Novavax and NINDS collaborate on E-selectin antistroke therapy

Galderma in-licenses PhotoCure's Metvix PDT skin cancer treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...